 "Datanomics: Surge in substandard drugs raises safety concerns in India")
Child deaths in Madhya Pradesh and Rajasthan after consuming a toxic cough syrup have once again highlighted the growing concern around substandard medicines in India, which fail the government’s Non-Standard Quality Drugs (NSQD) tests. In 2025, around 1,184 medicines were found to be substandard, with tablets accounting for 51 per cent, injections 18 per cent, and liquid formulations 11 per cent. The issue is not limited to domestic markets. India faced global scrutiny in 2023 when its cough syrups were linked to the deaths of dozens of children in Gambia.
Chart 1:
Medicines that failed NSDQ tests in India fell from 404 in 2019 to 322 in 2020, but later surged to 573 in 2022 and 1,184 in 2025.
Chart 2:
Out of seven states where substandard drugs have been seized, four have reported yearly rise, with West Bengal, Karnataka, and Maharashtra recording the highest shares in 2025.
Chart 3:
During the checks, regulators found that norms related to active ingredients were mostly violated.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%